Olema Pharmaceuticals (OLMA) News Today $6.11 -0.22 (-3.48%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$6.28 +0.17 (+2.78%) As of 01/31/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period JPMorgan Chase & Co. Buys 157,171 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)JPMorgan Chase & Co. lifted its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 658.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 181,032 shares of the company's stock after acquiring an additional 157,171 shares during the pJanuary 22, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Acquires 94,651 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 80.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 212,246 shares of theJanuary 19, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Buy" from AnalystsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) has been given a consensus recommendation of "Buy" by the six ratings firms that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month pricJanuary 16, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Bain Capital Life Sciences Inv Buys 300,000 SharesJanuary 14, 2025 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Acquires $1,728,000.00 in StockOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of Olema Pharmaceuticals stock in a transaction on Wednesday, January 8th. The stock was purchased at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the acquisition, the insider now directly owns 7,800,000 shares of the company's stock, valued at $44,928,000. This represents a 4.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.January 13, 2025 | marketbeat.comOlema Oncology files $200M mixed securities shelfJanuary 7, 2025 | markets.businessinsider.comOlema Oncology files to sell 27.53M shares of common stock for holdersJanuary 3, 2025 | markets.businessinsider.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comOlema Oncology to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comGeode Capital Management LLC Decreases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Geode Capital Management LLC lessened its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 11.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 934,929 shares of the company's stock aJanuary 1, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by BrokeragesShares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month tarDecember 22, 2024 | marketbeat.comG. Walmsley Graham Sells 700,761 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) StockDecember 18, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in StockOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director G. Walmsley Graham sold 700,761 shares of the company's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $6.75, for a total value of $4,730,136.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.December 17, 2024 | marketbeat.comWellington Management Group LLP Buys 97,428 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Wellington Management Group LLP grew its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 10.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,002,685 shares of the coDecember 15, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 207,565 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Charles Schwab Investment Management Inc. lifted its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 168.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 330,761 shares of the companDecember 15, 2024 | marketbeat.comHC Wainwright Has Strong Forecast for OLMA FY2024 EarningsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Investment analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for Olema Pharmaceuticals in a report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will earnDecember 13, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $77,358.72 in StockDecember 12, 2024 | insidertrades.comTD Cowen Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)December 12, 2024 | markets.businessinsider.comOppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)December 12, 2024 | markets.businessinsider.comOlema Pharmaceuticals: Promising Clinical Data and Growth Potential Warrant a Buy RatingDecember 12, 2024 | markets.businessinsider.comOlema Pharmaceuticals' (OLMA) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday.December 11, 2024 | marketbeat.comOlema Pharmaceuticals Advances Breast Cancer TreatmentsDecember 11, 2024 | markets.businessinsider.comOlema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer SymposiumDecember 10, 2024 | globenewswire.comOlema Pharmaceuticals Shares Rise 8.9% on FDA Approval of Cancer Drug ApplicationDecember 9, 2024 | marketwatch.comOlema: FDA Clears Investigational New Drug Application For OP-3136; Trial To Initiate In Early 2025December 9, 2024 | markets.businessinsider.comOlema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 InhibitorDecember 9, 2024 | globenewswire.comPoint72 Asset Management L.P. Acquires 475,447 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Point72 Asset Management L.P. lifted its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 14.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,687,374 shares of theDecember 5, 2024 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comStrategic Collaboration and Financial Backing Propel Olema Pharmaceuticals’ Buy RatingDecember 3, 2024 | markets.businessinsider.comPositive Outlook on Olema Pharmaceuticals: Strategic Collaborations and Promising Trial Results Boost Buy RatingDecember 2, 2024 | markets.businessinsider.comOlema Oncology, Novartis enter clinical trial collaboration and supply agreementDecember 2, 2024 | markets.businessinsider.comOlema Pharmaceuticals Secures Major Partnership and FundingDecember 2, 2024 | markets.businessinsider.comOlema: Cash Infusion And Supply Agreement With Novartis Carries The Tide ForwardDecember 2, 2024 | seekingalpha.comCiti Remains a Buy on Olema Pharmaceuticals (OLMA)November 29, 2024 | markets.businessinsider.comGreat Point Partners LLC Buys 203,120 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Great Point Partners LLC increased its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 25.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,000,000 shares of the company's stock after purchasing an additional 203,120 sharesNovember 27, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of "Buy" by BrokeragesShares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-monNovember 27, 2024 | marketbeat.comTD Cowen Remains a Buy on Olema Pharmaceuticals (OLMA)November 27, 2024 | markets.businessinsider.comOlema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer SymposiumNovember 25, 2024 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up - Here's WhyOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up - Here's What HappenedNovember 22, 2024 | marketbeat.comOptimistic Buy Rating for Olema Pharmaceuticals Driven by Promising Developments with Palazestrant and Novartis CollaborationNovember 22, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)November 21, 2024 | markets.businessinsider.comVictory Capital Management Inc. Has $10.17 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Victory Capital Management Inc. raised its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 9.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 851,512 shares of the company's stock after buying anNovember 21, 2024 | marketbeat.comFY2025 Earnings Estimate for OLMA Issued By Lifesci CapitalOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Investment analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Olema Pharmaceuticals in a research note issued on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky anticipates that the company will pNovember 15, 2024 | marketbeat.comHC Wainwright Has Pessimistic View of OLMA FY2024 EarningsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at HC Wainwright dropped their FY2024 EPS estimates for Olema Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($2.34) per shNovember 15, 2024 | marketbeat.comPromising Developments and Strategic Collaborations Bolster Buy Rating for Olema PharmaceuticalsNovember 14, 2024 | markets.businessinsider.comOptimistic Outlook for Olema Pharmaceuticals: Promising Clinical Data and Strategic Pipeline DevelopmentsNovember 14, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)November 12, 2024 | markets.businessinsider.comOlema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comOlema Oncology to Participate in Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 4, 2024 | globenewswire.com Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address OLMA Media Mentions By Week OLMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OLMA News Sentiment▼1.040.69▲Average Medical News Sentiment OLMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OLMA Articles This Week▼13▲OLMA Articles Average Week Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRIX News DYN News SPRY News PRAX News XNCR News ARDX News DAWN News ANIP News ARVN News OCUL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OLMA) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
